Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study

Submitted by Anonymous on

Oric Pharmaceuticals NASDAQ: ORIC reported updated Phase 1b data for enozertinib in previously untreated patients with advanced non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations, highlighting systemic and intracranial responses in a cohort with a high prevalence of baseline...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global...

Submitted by Anonymous on

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today presented potential best-in-class data...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

Submitted by Anonymous on

In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses 88% 6-month...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib...

Continued EGFR-TKI plus anti-angiogenic therapy versus chemotherapy after EGFR-TKI progression in EGFR-mutated non-small cell lung cancer: a real-world cohort study

Submitted by Anonymous on

AbstractBackground The optimal treatment after progression on epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for EGFR-mutated non-small cell lung cancer (NSCLC) remains unclear. We compared continuing EGFR-TKI therapy combined with anti-angiogenic treatment versus chemotherapy after EGFR-TKI progression. Methods This...

Signaling by RasG12V requires EGFR function in vivo to trigger full downstream pathway activation

Submitted by Anonymous on

Ras proteins regulate signaling pathways initiated by tyrosine kinase receptors, and activating Ras mutations are drivers in cancer and RASophaties. The development of therapies against these diseases requires a profound understanding of how Ras mutations modify pathway output and interact...

ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Submitted by Anonymous on

AstraZeneca today announced the US availability of ZEGFROVY® (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an...

ZEGFROVY (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations

Submitted by Anonymous on

AstraZeneca today announced the US availability of ZEGFROVY (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an...

BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer

Submitted by Anonymous on

SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with...

Subscribe to Newsfeed